2022
Characterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake
Oles W, Alexander M, Kumar N, Howell B, O’Connor P, Madden LM, Barry DT. Characterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake. BMC Psychiatry 2022, 22: 236. PMID: 35366844, PMCID: PMC8976510, DOI: 10.1186/s12888-022-03884-5.Peer-Reviewed Original ResearchConceptsLow-threshold clinicDemographic characteristicsOpioid use disorder treatmentMultivariate logistic regression modelBrief Pain InventoryPatient demographic characteristicsOpioid use disorderSocial supportSymptom Identification ScaleUse disorder treatmentNon-Hispanic whitesLogistic regression modelsOlder patientsPain InventoryTreatment cohortsSelf-reported social supportLife Events ChecklistMOUD treatmentBaseline disparitiesTreatment accessTreatment needsHigh riskUse disordersMortality rateDisorder treatment
2017
Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice
Donroe JH, Holt SR, O’Connor P, Sukumar N, Tetrault JM. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug And Alcohol Dependence 2017, 180: 46-51. PMID: 28866369, DOI: 10.1016/j.drugalcdep.2017.07.040.Peer-Reviewed Original ResearchConceptsOpioid use disorderUrine buprenorphineNorbuprenorphine levelsUrine adulterationAddiction treatment clinicsTreatment clinicsBuprenorphine medicationSublingual buprenorphineBuprenorphine treatmentTreatment cohortsRetrospective studyUrine specimenBuprenorphineUse disordersPatientsClinical practiceUrine samplesUrineClinicTreatmentMedicationsLevelsNorBUPCohortSuspicion